{"id":"dobutamine-injectable-solution","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Tachycardia"},{"rate":"10-20","effect":"Hypertension"},{"rate":"5-10","effect":"Arrhythmias"},{"rate":"5","effect":"Headache"},{"rate":"5","effect":"Tremor"},{"rate":"3-5","effect":"Chest pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dobutamine selectively stimulates beta-1 adrenergic receptors on cardiac myocytes, increasing the force of myocardial contraction (positive inotropic effect) and heart rate (positive chronotropic effect). This results in increased cardiac output and improved perfusion to vital organs. It is used acutely in patients with reduced cardiac output due to heart failure or cardiogenic shock.","oneSentence":"Dobutamine is a beta-1 adrenergic agonist that increases cardiac contractility and heart rate to improve cardiac output.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:45:57.335Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute decompensated heart failure with reduced cardiac output"},{"name":"Cardiogenic shock"},{"name":"Low cardiac output states requiring inotropic support"}]},"trialDetails":[{"nctId":"NCT06210217","phase":"EARLY_PHASE1","title":"Effect of TEE-guided Non-fluid Limited Combined With Dobutamine on Hepatic Venous Blood Flow Spectrum","status":"UNKNOWN","sponsor":"Sichuan University","startDate":"2024-02-01","conditions":"Laparoscopic Hepatectomy","enrollment":51},{"nctId":"NCT05594342","phase":"PHASE3","title":"Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support","status":"UNKNOWN","sponsor":"The Young Investigator Group of Cardiovascular Research","startDate":"2022-07-01","conditions":"Heart Failure, Cardiogenic Shock, Ischemic Heart Disease","enrollment":200},{"nctId":"NCT03659851","phase":"","title":"Levosimendan In Patients Undergoing LVAD Implantation","status":"UNKNOWN","sponsor":"University Hospital Dubrava","startDate":"2009-06-01","conditions":"Left Ventricular Dysfunction, Right Ventricular Dysfunction, Biventricular Failure","enrollment":50},{"nctId":"NCT02559141","phase":"NA","title":"Non-invasive Early Goal Directed Therapy in Colorectal Surgery: a Feasibility Study","status":"COMPLETED","sponsor":"University Hospital Schleswig-Holstein","startDate":"2014-03","conditions":"Perioperative/Postoperative Complications, C.Surgical Procedure; Digestive System","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dobutamine"],"phase":"phase_3","status":"active","brandName":"DOBUTamine Injectable Solution","genericName":"DOBUTamine Injectable Solution","companyName":"The Young Investigator Group of Cardiovascular Research","companyId":"the-young-investigator-group-of-cardiovascular-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dobutamine is a beta-1 adrenergic agonist that increases cardiac contractility and heart rate to improve cardiac output. Used for Acute decompensated heart failure with reduced cardiac output, Cardiogenic shock, Low cardiac output states requiring inotropic support.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}